Capital World Investors Buys 111,735 Shares of Jazz Pharmaceuticals PLC $JAZZ

Capital World Investors grew its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 4.4% in the fourth quarter, Holdings Channel reports. The fund owned 2,666,602 shares of the specialty pharmaceutical company’s stock after acquiring an additional 111,735 shares during the quarter. Capital World Investors’ holdings in Jazz Pharmaceuticals were worth $453,322,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of JAZZ. Hilltop National Bank bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at approximately $36,000. LRI Investments LLC bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at approximately $38,000. Danske Bank A S bought a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at approximately $40,000. Geneos Wealth Management Inc. boosted its holdings in Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 137 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in Jazz Pharmaceuticals by 1,383.3% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 332 shares during the period. 89.14% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Rick E. Winningham sold 2,741 shares of the stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $241.57, for a total value of $662,143.37. Following the sale, the director directly owned 9,567 shares in the company, valued at $2,311,100.19. This represents a 22.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Heather Ann Mcsharry sold 2,000 shares of the stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $241.00, for a total transaction of $482,000.00. Following the completion of the sale, the director owned 18,449 shares in the company, valued at $4,446,209. This represents a 9.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 10,741 shares of company stock worth $2,287,143 in the last three months. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $238.57 on Monday. The company has a 50 day moving average of $213.11 and a 200 day moving average of $187.01. The company has a market cap of $14.97 billion, a PE ratio of -11,922.54, a price-to-earnings-growth ratio of 0.22 and a beta of 0.32. Jazz Pharmaceuticals PLC has a 12 month low of $105.00 and a 12 month high of $243.32. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The business had revenue of $1.07 billion for the quarter. On average, sell-side analysts expect that Jazz Pharmaceuticals PLC will post 21.59 EPS for the current year.

Wall Street Analyst Weigh In

JAZZ has been the subject of several analyst reports. Leerink Partners raised their price objective on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a report on Wednesday, April 22nd. Piper Sandler raised their price objective on shares of Jazz Pharmaceuticals from $232.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, May 22nd. Morgan Stanley reaffirmed an “overweight” rating and issued a $245.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, May 7th. Robert W. Baird set a $252.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Finally, Truist Financial raised shares of Jazz Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $242.65.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.